Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Medication Talk - Expert Insights on Drug Therapy & Patient Care

Medication Talk - Expert Insights on Drug Therapy & Patient Care artwork

Managing Nonalcoholic Fatty Liver Disease

Aug 1, 202228 minAudio
ShareXLinkedInFacebookWhatsAppEmail

TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Kenneth Cusi, MD, FACP, FACE, Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism from The University of Florida about managing nonalcoholic fatty liver disease. Listen in as they discuss considerations with managing nonalcoholic fatty liver disease (NAFLD)...including risk factors, screening, and treatment options. You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board: Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson University Douglas S. Paauw, MD, MACP, Professor of Medicine at the University of Washington School of Medicine Craig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science University For the purposes of disclosure, Dr. Cusi reports relevant financial relationships with Echosens, Inventiva, Nordic Pharma, Novo Nordisk, Poxel, Zydus (grants/research support); Ionis, Janssen, Genentech, Gilead, Madrigal, Merck, Novo Nordisk, Pfizer, Poxel, Terns Pharmaceuticals (consultant). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated. Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses. Claim Credit 🗪 Send us Fan Mail Email us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Medication Talk is a production of TRC Healthcare. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here. Learn more about our product offerings at trchealthcare.com.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

NarratorWelcome to Medication Talk, the official podcast of TRC Healthcare, Homo pharmacist letter, prescriber's letter, RX Advanced, and the most trusted clinical resources. On today's episode, we'll be listening in as our expert panel discusses considerations with managing non-alcoholic fatty liver disease, including risk factors, screening, and treatment options. Our guest today is Dr. Kenneth Cusey from the University of Florida. You'll also hear practical advice from panelists on TRC's Editorial Advisory Board, Dr. Anthony Donato from the Reading Health System, Dr.

NarratorDouglas Powell from the University of Washington School of Medicine, and Dr. Craig Williams from the Oregon Health and Science University. This podcast is an extract from TRC's Emerging Recommendations panel webinar. Each month, experts and frontline providers discuss current medication therapy topics and practical recommendations to include in TRC's Letter articles. The full webinar originally aired on June 16th, 2022.

CE NarratorAnd now, the CE information.

NarratorPharmacist Letter offers CE credit for this podcast. Please log into your Pharmacist Letter account and look for the title of this podcast in the list of available CE courses. For the purposes of disclosure, Dr. Coosty reports relevant financial relationships by receiving grants or research support or being a consultant for Ecosyns, Inventiva, Nordic Pharma, NovoNordisk, Poxil, Zytis, Ionis, Jansen, Genitech, Gilead, Madrigal, Merck, Pfizer, and TERNS Pharmaceuticals.

NarratorThe other speakers have nothing to disclose. All relevant financial relationships have been mitigated. Now let's join TRC editor, Dr. Lori Dickerson, and start our discussion.

Lori DickersonAnd we're discussing this topic now because you'll get questions about how to manage patients with non-alcoholic fatty liver disease due to new guidelines. And Ken, we appreciate you joining us to discuss this important topic. And to get us started, I was hoping that you could briefly comment on why the new American Association of Clinical Endocrinology Guidelines specifically call out the management of non-alcoholic fatty liver disease in primary care, even in the guideline title. So it seems like we're driving that home to primary care.

Kenneth CusiYeah, you're right, Lori. Thank you for having me. Well, this has been a long effort in trying to affect the prevalence of uh cirrhosis in high-risk people before they it's too late. So you should know that now uh the it's very soon the number one cause of liver transplantation is Nash. Um and the highest risk groups have a very high prevalence of this, and there are some things, simple things you can do to prevent that.

Kenneth CusiUm so answering your question, how common it is, uh, well, non-alcoholic fatty liver disease is uh is like an umbrella term that from having just fat in the liver, triglycerides, all the way to having inflammation and then fibrosis. So it's a little bit confusing, but it's important for pharmacists because they're two separate things. If you have fat in the liver, that's a reflection of insulin resistance. So your liver is really like your mirror of your metabolic health.

Kenneth CusiThat's going to be associated with increased cardiovascular risk. And what pharmacists should do is um work uh even harder on reducing cardiovascular risk with statins that shouldn't be stopped, um, and and the standard traditional management of risk factors. But the second thing is treating the liver disease that will lead to cirrhosis in about 3 to 5% of high-risk patients.

Lori DickersonOkay, great overview, Ken. I appreciate you getting us started. You know, we do actually start the article uh off by calling it a sleeper epidemic, and I'm just wanting to confirm that you agree with that with that term.

Kenneth CusiAbsolutely, because neither the doctors, primary cares, or endocrinologists, as an endocrinologist, I'm a little bit ashamed yet about this, but they're not doing enough to find these people and do things that that would really have a huge impact. And um they just show up with cirrhosis at the liver clinic. That's that's something that we want to change.

Lori DickersonAnd uh, of course, as you've mentioned, um many of these patients, and we are actually updating our statistic in the article to say up uh up to one in seven of these patients um have NASH or non-alcoholic steatohepatitis, which is of course the more aggressive form of NAFLD, that can lead to fibrosis and cirrhosis and liver cancer. And so uh just wondering if you agree with uh sort of that range, one in seven, Ken.

Kenneth CusiYeah, yeah. So that there are there are like three diseases in one. So let me just um help you here. So uh if you have the if you take the people at the highest rates, or people with type 2 diabetes or prediabetes, if you take a hundred of such patients, 70% have fatty liver, this accumulation of triglycerides. Now, about half of those will have this inflammation, which you call statopatitis. That's the active disease that's promoting uh the um fibrosis and cirrhosis.

Kenneth CusiAnd one in seven will have fibrosis, significant fibrosis. In other words, uh it's like having put nuria and diabetic nephropathy. So one in seven have a degree of fibrosis that, if left alone, it may lead to cirrhosis. And that's what we're trying to identify with screening. Not so much the fat, but the risk of fibrosis. And we can do that with a couple of simple tests.

Lori DickersonI do want to get into those tests because since we last wrote about this, can the Fib 4 index has been recommended as a tool to identify fibrosis. And so can you expound a little bit on this tool, its pros and cons, and sort of when when you would recommend its use in primary care practice?

Kenneth CusiYeah, so in older guidelines, there was some emphasis on ultrasound, but it's a worthless test because now we know that seven out of ten people with obesity and or type 2 diabetes already have fat. What we're trying to identify are who of those that have scarring in the liver, what we call fibrosis. So, why Fib 4? First, very cheap. You already have it in your electronic medical record. There are calculators that Epic has, so um it's it's there.

Kenneth CusiUh or you go to any uh website. The reason why FIB 4 is adopted, not because it's very sensitive, but it's very specific. In other words, now there's good evidence that it's associated with cirrhosis, risk of even liver cancer, and increased mortality. So that's why learning a couple of cutoffs below 1.3, you would say that you are likely okay with some caveats, and above 2.6, you're probably in risk of cirrhosis.

Kenneth CusiThose are the numbers you need to remember and then order a second test. Or pharmacists could bring this to the attention of busy doctors, um, primary care doctors who uh are going to be uh identifying most of these people in the future.

Lori DickersonThat's a great overview. And Doug, I wanted to hear from you. Is this uh test that you're using your practice now? And um, when are you when are you uh choosing to to check this? Calculate this.

Douglas S. PaauwAs pointed out, we have all this information on most of our pay, pretty much all our patients. We have these labs, so it's it's pretty easy to do. And uh it's just a matter of sort of having it be part of the standard uh approach to patients with with uh pre-diabetes, diabetes, high-risk patients.

Lori DickersonOkay, so sort of, yeah, so bringing it into the general management of those folks to just standardly uh calculate this this index um rather than, of course, because it's an asymptomatic condition, waiting for someone to present with symptoms, right?

Kenneth CusiIt does call for a paradigm change because you're not used to doing as endocrinologists, you know, and primary care, we do a lot of things. But you can we you can in Epic, for example, we there's a calculator you can have, you can do a dot fib four, and it automatically calculates if you have those uh raw um labs in your note. And we even develop a uh a clinical care pathway to when to send to that liver doctor. So um, and I've also worked uh in the VA, um, and it they this this data is easily retrievable.

Kenneth CusiWe just need to develop the the muscle in the same way as we did for um measuring protein in the urine in diabetic nephropathy or in a bone density in high risk groups, et cetera. Hey Lori, this is this is the answer.

Anthony A. DonatoYes, yes, indeed. The nice thing for um uh things like uh kidney failure is creatinine's obvious. It comes up with a big H on the screen. For this, you can actually have normal AST ALT, uh, but just a flip ratio and a platelet count that's nearly normal, none of it lights up and they could have cirrhosis. Um, and I think that the the key thing is we have to actually go looking for it. I think what's been brought up here is I think we need to get into the habit of doing this or even have systems in the hospital that actually calculate this for us automatically in the background and put it in our faces because we don't otherwise look for it.

Kenneth CusiWell, those are excellent points.

Lori DickersonYeah, those are great points. No, I appreciate you you bringing that up, Andy, and you reiterating that, Ken, because I think you know, our my wording, or our wording here in the article where we say consider screening is you know, you know, get into the habit of screening, you know, and be a little stronger.

Kenneth CusiAnd again, to be honest, we know what the limitations of the FIF4. It's not very sensitive. As said, there's there are people with moderate to advanced liver disease that have values of that are below 1.3. We we know that. But as a first test um that would be you know easy to get away from the cost-effectiveness uh debate, um, we want to use it to begin catching at least that 80% uh that are at risk. So anybody who's the above 1.3 probably needs to get a second test or see a hepatologist.

Kenneth CusiSo we know it's a bad test. We know there are better ones down the pipeline. We just want to develop the muscle for screening at this point.

Craig D. WilliamsAnd Laura, can I ask a question on this topic of screening? The I've always presumed that the insulin resistance plays some role in this in the hyperinsulinemia, but Kenneth might have mentioned this. How often are non-diabetics getting screened and positive for this?

Kenneth CusiWell, I I unfortunately not very often. So the big three groups at at risk are people with prediabetes or type 2 diabetes, um, people who have obesity and the metabolic syndrome, and the third of those with statosis on any imaging and um ALT above 30, not 40. Um, so it's not being done. So the question is, are we gonna screen the entire population of the United States? And I think that that's we need to get have more data for that.

Kenneth CusiMy our recommendation, let's start with the highest risk group, which is clearly people with type 2 diabetes or or pre-diabetes.

Lori DickersonVery good point. So I want to move us along to talk about treatment because we do have lots to say here. And you know, we do make the point, Ken, that the tough part is that there's not good evidence that meds decrease the risk of cirrhosis, liver transplant, or death. And um I think that you know the evidence is evolving to answer those questions. Uh, but I just want to be sure that you agree with that statement and that this is a you know a treatment in evolution.

Kenneth CusiCorrect. So it's gonna take us 20 years, given the natural history of cirrhosis. Um, but we have drugs that can um reverse the statopatitis and have some effect on fibrosis. Uh, and I think that that's what the guidelines have adopted as a surrogate until we have this long-term data.

Lori DickersonExcellent. Okay, well, let's uh jump into management. And we do make recommendations about weight loss as the most important treatment. And a loss of over 5% reduces liver fat, and over 10% can reverse fibrosis. And so again, Ken, checking to see if uh you would agree with that statement as um as having that sort of impact.

Kenneth CusiYeah, yeah, it's it's an easy to remember with a lot of caveats that we don't have time. If you just reduce saturated fats without reducing weight, there's going to be some improvement. Adopt a Mediterranean diet, things get better without that. And these numbers are not magic numbers. There's a lot of um noise about these uh numbers and variability. But in general, the greater weight loss, uh, by any means, uh lifestyle changes and exercise, pediatric surgery, medications that induce weight loss, there is improvement with the greater, it's harder to reverse fibrosis, um, easier for the inflammation, the statopatitis.

Lori DickersonAnd Andy, you brought up the good point in your earlier review of the article about uh advising avoiding alcohol and including that in the um in the article. And um, so we did include that and just how that can increase the risk and progression of liver damage. So I appreciate you bringing bringing that up. And I guess, Ken, I I'm assuming you would agree with that statement.

Kenneth CusiUh yes, for the most part. I have to say that this is a point of great debate in the liver field. Um, if you have early, if you don't have fibrosis, you have early stages. I mean, um, using this, you know, with prudence, uh a glass of wine or one or a beer can be tolerated. As you advance to have more advanced fibrosis, stages um uh three, four, or of course cirrhosis, you want to avoid it. But but uh you can drink with moderation in the early stages.

Kenneth CusiGotcha.

Lori DickersonOkay. And of course, uh from a primary care standpoint, we we've already mentioned the importance of optimizing meds for dystalpidemia, diabetes, hypertension, and tamping down on that insulin resistance and uh and weight loss. And so, Doug, just uh to hear from you in your practice, these are things that you're working on in terms of uh once you've identified these folks with um NFLD. Would you agree?

Douglas S. PaauwYeah, and and I think when you when you when you when you find it, I think it's a huge motivator for for lifestyle change. I think so often we talk about our patients, and I think when we we have an end organ problem and and we sort of say, you know, now is the time, I found it really, really positive for my patients and adopting a real real attempt to lose weight and really putting all their energy into it. So I I think it gets back to why it's so important to screen for this and and to because you can get the lifestyle changes bought in and that we're gonna help all the other diseases too that these patients have.

Lori DickersonGood points. And you know, we have several questions coming in about statins and their safety in folks with fatty liver disease. This is a common question that we get because we you know typically think about uh, you know, liver function test monitoring with statins. So, can we make the point um to keep in mind that statins are safe in NFLD and even in NASH? Uh, can you comment on on this statement and if you agree?

Kenneth CusiYeah, so the liver society say that they're safe and every other society in the world. Um, again, you need to be monitoring the patient as you would do. Uh, we we follow prospectively a group of 100 people with biopsy-proven Nash and fibrosis, and it was safe. We only had to stop it in one person that later admitted to excessive alcohol intake. And because they have higher cardiovascular risk, is that you don't want to um stop them. So um I would say for the most part, uh, if the liver enzymes are within two and a half or threefold above normal, you start low and slow and monitor it.

Kenneth CusiUm, and and they're all overall safe. And remember, you don't want to take them from people with increased cardiovascular risk because cardiovascular disease is the number one killer in people who have Nash and fibrosis, of course, until you get to the late stages of living disease.

Lori DickersonRight, right. And just to clarify, Ken, we're using statins in this situation to reduce cardiovascular disease risk. Um, are is there, is there an impact of statins on uh progression to NASH from an FLD?

Kenneth CusiGreat question. So statins have a number of favorable biological effects on the patocytes, but there are a number of small short-term randomized control trials that have not shown any major effect on the inflammation or fibrosis. So the use would be to treat cardiovascular disease primarily.

Lori DickersonGot it. Okay, so let's actually talk about some of the treatments then. We do recommend P.O. glutosone or injectable subaglutide first line. And um, Ken, I'm just uh checking, these are your sort of go-to agents, and then we'll tease through the two and when you might choose one or the other. But do you agree in general with the statement?

Kenneth CusiYeah, so number one, there's no FDA-approved medication. So we're using these agents with a dual purpose, either to treat diabetes and NASH or treat obesity and NASH in the case of Wigovi. And um, they have the best evidence, of course, uh, none of these studies that have been treated for more than um two or three years. So uh it's it's it's it's good evidence from those randomized controlled trials, but we the we do need long-term trials which are underway now.

Lori DickersonAnd Doug, I'm curious in your practice, is this something that you would be, you know, d starting, or would they be going to GI and hepatology to start Plydozone or submeglide and then coming back to you? Uh how how does that work in your practice?

Douglas S. PaauwYeah, I feel very comfortable treating it. I I just I you know the I I have not been a real super big fan of pyoglydozone in general, um, and some of the some of the other issues that occur, especially edema with it in my patients. So I've you know, our liver folks sometimes use it. Uh the the other medication I think has a lot more promise to me as far as selling it to the patient and keeping them on it. So, yes, I feel comfortable doing it. And our certainly our liver folks feel very comfortable.

Lori DickersonYou know, I'm glad you brought that up, Doug, because we do have questions coming up uh about this, and we did get some questions on peer review about this. You know, it's so we understand P.O. glutathione's oral, it's you know low cost, those seem like benefits, but you know, edema and weight gain are problems with and pee-glottosone, and then we're of course trying to have these patients lose weight. So uh it seems um a little counterintuitive. So, Ken, um just wondering if you can comment on that.

Kenneth CusiAbsolutely, that's a great point, Laurie. So, to understand what we are treating in Nash, we are treating insulin resistance in the adipose tissue. So you're when you are obese, and even when you're overweight but have insulin resistance, uh, which is also genetic and acquired uh component to it, what's happening is your adipose tissue is releasing fatty acids to your liver around the clock. It's like an infusion of toxic lipids to your liver.

Kenneth CusiThere are two ways you can reverse that. A, reduce the mass of adipose tissue. So if you lose weight, you're you have to lose a significant amount of weight for your adipose tissue to be healthy again. Pyoglitosone takes the other route, targets adipose tissue, and makes it work like the adipose tissue of a lean person retaining fat in the right place. So that is why pyoglidosone can uh not only treat diabetes and NAS, but reduces cardiovascular disease.

Kenneth CusiAnd most recently the iris study showed that in about 3,000 people, where it reduced cardiovascular disease, stroke, MIs, etc. So, how do we avoid the weight gain? And how much weight gain do you get? Well, it is dose-dependent. So if you use 15 milligrams, the weight gain in about nine different studies is about 1%, and the rate of edema is very low, I would say 2 or 3%. So it can be used safely. Now, the efficacy in NASH is not being shown yet with 15 milligrams, but it does improve lipids and lowers glucose.

Kenneth CusiThe 30 milligrams was shown in a large randomized trial called Pivans, and that did improve NASH in um the vast in about 50% of the people. Um, so again, the weight gain with 30 milligrams can be three or four percent, but it can be mitigated if you do lifestyle or add a GLP1. So, and it's much cheaper. Like I worked, um, you know, pyo cost is five dollars for per month, and semi-glutide costs we never know how much it costs, but it's eight, nine, or a thousand dollars.

Lori DickersonYes, for sure.

Kenneth CusiI got a patient who called me, hey, you gave me medication costs eight hundred dollars, doctor. Give me something real.

Lori DickersonRight, right, right.

Kenneth CusiSo several hundred people with pyoglutosome uh compared to a GLP1.

Lori DickersonSo great points, and certainly uh payer coverage is gonna be a big part of this. Um, and so uh let's actually talk about semaglutide, injectable semaglutide. And you know, we're uh that is uh under the brand name Mosempic or Wagovi is the higher dose. Of course, it's for obesity. And uh we're gonna ty we recommend titrating those towards the max doses for the most benefit. Um, and uh, but of course, the cost is uh we say over $900 or up to $1,000. And we have, of course, side effects with these agents, like the GI side effects.

Lori DickersonWe can have some pancreatitis also. And so actually, Doug, I was curious, are you having uh issues with getting the semiglutide approved for your patients? Uh, or is just the documentation of um fibrosis enough to uh to help get that through that hurdle?

Douglas S. PaauwIt depends which it depends which uh insurance company. I've been able to get it in some people, but sometimes it's a real battle.

Lori DickersonKen, do you have any tricks there to help? Yeah, definitely.

Kenneth CusiSo if you say if you say the patient has Nash or fibrosis, you're not gonna get it approved, unfortunately. Uh because it doesn't have an indication for that. So a SEMPIC would be now can be pushed up to two milligrams. You start at 0.25, bump it up to 0.5, etc. Um for diabetes, but typically they're gonna ask you that they failed some other uh oral agent before.7 up to 2.4.

Kenneth CusiThat dose is equivalent to the dose of the trial published in Nash, um, that we published in Nash last year in the New England. So it that will have to go through the hurdles of managing obesity, which is even worse than for a SEMPIC. So easier to get a SEMPIC than we govi. Um, but but again, um it is worth the effort to try.

Craig D. WilliamsIt is not easy to get GLP1 still, but often you can get the one that that insurer prefers. But so we mean to call out some glue.

Lori DickersonYou read my mind, Craig. I just lost your audio for a second there. Yes. Yes, we we do uh we do recommend one of these agents um uh because there's not much evidence with the others. And so, Ken, would you agree with that?

Kenneth CusiYes, so there are small trials with accenatide and a handful of people, an uncontrolled study with looking at a reduction in fat but no biopsy. Lida glutide had a trial called lean, uh uh published in the Lancet several years, only 50 people, some histological benefit. Uh with semaglutide, last year in the New England, the first also Dr. Newsom uh showed in um over 72 weeks to have improvement on statopatitis.

Kenneth CusiThey didn't get to significance in terms of fibrosis, but decreased the progression of fibrosis. So that's why semiglutide has been um the drug with the greatest evidence. But you should know that uh well, tiersepathite that has been approved for diabetes, um, it has uh NASH trial that is under underway, uh phase two trial. So we'll hear more about the other agents in the near future. But for now, semi-glutide has the evidence.

Lori DickersonSorry, I didn't mean to interrupt you. We're almost out of time, but I do want to clarify one point. Um, we are talking about using these drugs, uh p.glitosone and semi-glutide, uh to reduce liver fat, slow fibrosis progression, uh, regardless of whether or not the patient has type 2 diabetes. So if they did or didn't, is that what is your thought there?

Kenneth CusiWell, studies have shown that people without diabetes respond to pyoglizone 2, but you cannot prescribe these drugs for NASH. They're not FDA approved for NASH. So when you have somebody with diabetes and NASH, you're going to prescribe uh for the diabetes uh with that purpose of improving their Nash. And if they don't have diabetes, um you can prescribe pyoglitosone, but you can prescribe um wagobi that has an indication for obesity. I see. Gotcha. So I hopefully that's that's clear for the audience.

Lori DickersonYes, very good, very good. Uh we're almost out of time. I want to um uh just briefly ask about vitamin E and milk thistle. We are getting lots of questions in about uh supplements, and um we do make the recommendation to not jump to either of these, uh, you know, lack of evidence as well as um uh or or I guess spotty evidence, and then also risks associated with vitamin E in cardiovascular patients. So just uh briefly, Ken, what are your thoughts on supplements here?

Kenneth CusiIn a nutshell, PVEN study showed vitamin E improved tetapatitis, but not fibrosis. Again, as you say, some might now suggest not only increased cardiovascular disease, but uh increased risk of prostate cancer. We did a trial combining uh with pyre vitamin E and another arm vitamin E alone with some benefit, but again, in a population with increased cardiovascular risk, everybody's a little bit nervous. And answering no other things have shown to work in Nash so far. There are many agents, um, like Milkviso has not shown to work.

Kenneth CusiEverything has been thrown at patient with Nash, most of them unsuccessfully.

Lori DickersonGreat points, Ken. I appreciate all of that. And I guess just to close out, Doug, anything further that you would like to add in terms of managing these folks in your patient population?

Douglas S. PaauwI think just to reiterate that that I think the most important thing is when these things, when these patients come to your attention, that you know, using that as a time to really change their lifestyle, because as pointed out, a lot of the therapies are are are hard to get and aren't aren't particularly strong, but you know, the weight loss and lifestyle change probably has good or better than anything else.

NarratorWe hope you enjoyed and gained practical insights from listening into this discussion. Now that you've listened, you can receive CE credit from Pharmacist Letter. Just log into your Pharmacist Letter account and look for the title of this podcast in the list of available CE courses. If you're not yet a Pharmacis Letter subscriber, find out more about our product offerings at TRCHealthcare.com. Be sure to follow or subscribe, rate, and review this show in your favorite podcast app. It helps spread the word about our show and is a great way for you to let us know how we're doing. You can also reach out to provide feedback or make suggestions by emailing us at contact us at trchealthcare.com.

NarratorThanks for listening to Medication Talk.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Navigating Obesity Treatment

    Nov 1, 202634 minAudio

    Listen in as our expert panel walks through today’s full range of obesity treatment options - from older agents like orlistat and phentermine/topiramate to the latest GLP-1 therapies - and how to match the right...

    Credit the people on this episode

  2. Feed Drop: Toxic Yellow Oleander in Weight Loss Products

    Oct 15, 202624 minAudio

    A bonus episode from our sister show, Natural Medicines: Evidence in Practice. Weight loss supplements labeled tejocote, Nuez de la India, or Brazil seeds have been found to contain toxic yellow oleander, and as few as...

    Credit the people on this episode

  3. Managing Poisonings

    Oct 1, 202633 minAudio

    Poisonings are a significant public health concern - in 2024 alone, U.S. poison centers received over 2 million reported exposures. Listen in as our expert panel of toxicologists and poison-center specialists discusses...

    Credit the people on this episode

  4. Decoding the Lipid Guidelines

    Sep 1, 202633 minAudio

    Listen in as our expert panel breaks down what clinicians need to know about the 2026 dyslipidemia guidelines, such as the role of lipoprotein a, apolipoprotein B, and coronary artery calcium scoring. Plus, you'll walk...

    Credit the people on this episode

  5. Estimating Kidney Function in Chronic Kidney Disease

    Aug 1, 202633 minAudio

    Listen in as our expert panel untangles the latest recommendations for using equations to estimate kidney function. You’ll hear their insights on when and how to use creatinine, cystatin C, or both to help safely adjust...

    Credit the people on this episode